- AtomVie Global Radiopharma has entered a strategic partnership with Jubilant Radiopharma to provide logistics, regulatory compliance, and last-mile distribution services for AtomVie-manufactured radiopharmaceuticals across the United States.
- The agreement will use Jubilant Radiopharma’s U.S. pharmacy network to support delivery to clinical trial sites and strengthen AtomVie’s integrated service offering.
AtomVie Global Radiopharma, a radiopharmaceutical contract development and manufacturing organization (CDMO), has entered a strategic partnership with Jubilant DraxImage Inc., doing business as Jubilant Radiopharma, to support logistics, regulatory compliance, and last-mile distribution for its growing portfolio of radiopharmaceutical programs. The collaboration is governed by a Logistics and Regulatory Services Agreement between the two organizations.
Under the agreement, Jubilant Radiopharma will manage the receipt, handling, regulatory compliance, and last-mile distribution of AtomVie-manufactured radiopharmaceuticals through its U.S. pharmacy network. The arrangement is intended to streamline deliveries to clinical trial sites while maintaining the quality, safety, and regulatory compliance standards required for radiopharmaceutical products.
The partnership will draw on Jubilant Radiopharma’s distribution infrastructure and capabilities in clinical trials, therapeutic dispensing, and commercialization. AtomVie and its clients are expected to benefit from improved access to clinical trial sites and greater operational flexibility as development programs progress.
“The collaboration would support the company’s expanding clinical development programs through Jubilant Radiopharma’s pharmacy network and regulatory expertise.”
Bruno Paquin, CEO of AtomVie
Harsher Singh, CEO of Jubilant Radiopharma, said the agreement reflects both organizations’ commitment to the safe and compliant delivery of radiopharmaceutical therapies and expanding patient access to new treatments.
